Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Published:2023-08 Issue:8 Volume:22 Page:661-671
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Giladi Nir,Alcalay Roy N,Cutter Gary,Gasser Thomas,Gurevich Tanya,Höglinger Günter U,Marek Kenneth,Pacchetti Claudio,Schapira Anthony H V,Scherzer Clemens R,Simuni Tanya,Minini Pascal,Sardi S Pablo,Peterschmitt M Judith

Funder

Sanofi

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference32 articles.

1. GBA-Associated Parkinson's disease and other synucleinopathies;Gan-Or;Curr Neurol Neurosci Rep,2018

2. Non motor subtypes and Parkinson's disease;Sauerbier;Parkinsonism Relat Disord,2016

3. The genetic architecture of Parkinson's disease;Blauwendraat;Lancet Neurol,2020

4. Parkinson's disease and the environment;Ball;Front Neurol,2019

5. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease;Sidransky;N Engl J Med,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parkinson’s Disease;International Encyclopedia of Public Health;2025

2. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease;Translational Neurodegeneration;2024-09-12

3. Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease;Movement Disorders;2024-09-11

4. Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies;Cellular and Molecular Life Sciences;2024-09-03

5. Gaucher disease provides a unique window into Parkinson disease pathogenesis;Nature Reviews Neurology;2024-08-06